Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report Q2, 2020

Second quarter 2020 All figures for 2020 and 2019 refer to the Group.Other operating income amounted to kSEK 872 (663)   · Result after taxes amounted to kSEK -4,810 (-4,149)   · Basic and diluted earnings per share: SEK -0.05 (-0.05) · The cash flow from operating activities was kSEK -5,775 (-3,547) First half of 2020 · Other operating income amounted to kSEK 2,057 (1,313). · Result after taxes amounted to kSEK -8,594 (-6,925)   · Basic and diluted earnings per share: SEK -0.10 (-0.08) · The cash flow from operating activities was kSEK -5,342 (-3,576) ·

Saga Tankers Asa – Key Information Relating to the Proposed Cash Dividend

Reference is made to the stock exchange notice issued on 25 August 2020 regarding a decision by the Board of Saga Tankers ASA to distribute dividends of NOK 0.10 per share. The key information of the cash dividend is as set out below: Dividend amount: NOK 0.10 per share. Declared currency: NOK Last day including right: 26 August 2020 Ex-date: 27 August 2020 Record Date: 28 August 2020 Payment Date: On or about 4 September 2020 Date of approval: 25 August 2020  * * * For further information, please contact:CEO Espen Lundaas+47 92 43 14 17 This information is

Hexagon Composites ASA: Invitation to presentation of Hexagon and its Spin Off plans for Hexagon Purus

Reference is made to the stock exchange announcement on 24 August 2020, regarding the intended Spin Off and listing of Hexagon Purus.Jon Erik Engeset, CEO and Morten Holum, President Hexagon Purus will present Hexagon and the intended Spin Off today, 25 August 2020 in a webcast at 10:00 CEST. You can follow the presentation here  or via www.hexagongroup.com A recording of the presentation will be made available on www.hexagongroup.com after the presentation. Contacts: Karen Romer, SVP

Today Marks the Release of Descenders, Published by Sold Out

Today, EG7 announces that the title Descenders, published by Sold Out, is released. Descenders is developed by No More Robots and published by Sold Out and is a fast-paced cycling game with procedurally generated tracks where mistakes have real consequences. Today, August 25, 2020 marks the release of Descenders on Playstation 4 both physically and digitally. The title will also be released physically and digitally on Nintendo Switch later this year. Comment from Robin Flodin, CEO of EG7: "We are very excited to now be able to give Playstation players the opportunity to play

Notice to Extra General Meeting in ExpreS[2]ion Biotech Holding AB (publ)

The shareholders of ExpreS[2]ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the extra general meeting to be held on Wednesday 23 September 2020, at 10.00 at meeting room Penthouse at Mindpark, Bredgatan 11 in Helsingborg. This is an unofficial translation of a notice to the Annual General Meeting in ExpreS[2]ion Biotech Holding AB, originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail.Information with respect to the coronavirus Due to the development of the

SAGA TANKERS ASA: DIVIDEND DISTRIBUTION OF NOK 0.10 PER SHARE RESOLVED

Reference is made to the stock exchange notice of 21 August 2020. The Board of Directors of Saga Tankers ASA (the "Company") has now resolved to distribute a dividend of NOK 0.10 per share. The dividend is resolved pursuant to a Board authorization granted by the general meeting of the Company. The dividends will be payable to the shareholders of the Company as of 26 August 2020, as registered in the VPS on 28 August 2020. The dividends are expected to be paid on or about 4 September 2020. For further information, please contact: CEO Espen Lundaas +47 92 43 14 17 This

AlzeCure publishes its interim report for January – June 2020

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January – June 2020 is now available on the company’s website:  https://www.alzecurepharma.se/en/section/investors/financial-reports/“With yet another eventful quarter behind us we can conclude that AlzeCure’s operations are progressing well and according to plan, with continued advances in all of our three project platforms: NeuroRestore, Alzstatin and Painless. One important milestone that we achieved is the conclusion of a clinical trial for the NeuroRestore project ACD856, with positive

Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center

Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer. Diaprost is a private pharmaceutical research and development company based in Lund, Sweden and whose principle asset is h5A10, targeting PSA, a validated clinical biomarker.  The h5A10 antibody combined with the appropriate payload offers the potential for highly specific therapeutic and diagnostic products, for example as a therapeutic product to deliver cytotoxic

Finnair closes a sale and leaseback agreement for one of its A350 aircraft

Finnair Plc           Investor News      25 August 2020 at 9.00 a.m. EEST Finnair has finalised a sale and leaseback arrangement for one of its A350 aircraft with Nomura Babcock & Brown Co., Ltd. (“NBB”), and BBAM Aircraft Management LP as an arranger and lease servicer. In the arrangement, Finnair sold the Airbus A350 aircraft delivered in February 2020 to NBB and leased the aircraft back for its own operation. The initial operating lease period is 12 years, and the lease includes extension options. The arrangement has no major impact on Finnair’s operating result for the third

Today Marks the Release of No Straight Roads, Published by Sold Out

Today, EG7 announces that the title No Straight Roads, published by Sold Out, is released. Developed by Metronomik and published by Sold Out, No Straight Roads is an action-adventure game that mashes together rhythm-infused combat with a vibrant offbeat world and a killer soundtrack. Today, August 25, 2020, marks the digital release of No Straight Roads on PlayStation 4, Xbox One and PC exclusively via the Epic Games Store. A physical version will be available for the Nintendo Switch on September 15, 2020. No Straight Roads is Sold Out's biggest digital investment to date. Comment

ExpreS2ion announces up to SEK 216 million capital raise through a fully guaranteed rights issue to finance ground breaking vaccine and immunotherapy pipeline

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE INFORMATION: Hørsholm, Denmark, August 25, 2020 – The Board of Directors of ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) has today, subject to approval by the Extraordinary General Meeting (“EGM”) to be

Calliditas appoints Group General Counsel

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced the appointment of Jonathan Schur as Group General Counsel, effective October 1, 2020.Jonathan Schur has over 30 years of experience as a lawyer and is a member of the New York and Paris Bars. His practice focuses on work for pharmaceutical companies at all stages of development, from biotech companies advancing breakthrough technologies, to specialty and large pharmaceutical companies building commercial franchises. Having practiced in Paris for most of his career, Jonathan bridges the gap between the US and European legal

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

25 August 2020 07:00 BST Phase I clinical trial initiated for monoclonal antibody combinationfor the prevention and treatment of COVID-19 First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19. The trial, called NCT04507256, will evaluate the safety, tolerability and pharmacokinetics of AZD7442.[1] The trial will include up to 48 healthy

The Board of Directors of Detection Technology decided to issue stock options

Detection Technology Plc company announcement 25 August 2020 at 9:00 (EEST) The Board of Directors of Detection Technology decided to issue stock options Based on the authorization granted by the Annual General Meeting of shareholders held on 16 April 2020, the Board of Directors of Detection Technology Plc has decided to issue stock options on the enclosed terms and conditions. The stock options shall be offered free of charge to key personnel of the Detection Technology group. There is a weighty financial ground for the company for the issuance of the stock options as the stock

Notice for Annual General Meeting of Flexion Mobile Plc

If you are in any doubt as to what action you should take, you are recommended to seek your own financial advice from your stockbroker or other independent adviser authorised under the Financial Services and Markets Act 2000.Chairman’s letter to shareholders regarding Notice of Annual General Meeting   Dear Shareholder, Please take notice that this year’s annual general meeting (“AGM”) will be held at 2.00 pm on Thursday 24[th] September 2020 at Flexion Mobile Plc, Unit G5, Harbour Yard, Chelsea Harbour, London, SW10 0XD, UK.  Full details of the meeting, location, business to be

Veidekke ASA: To renovate property in Hagastaden, Stockholm

The Veidekke subsidiary Arcona has been commissioned to reconstruct and renovate the property Skålen 24 in Hagastaden, Stockholm.The client is Scius Partners, and the contract value is SEK 400 million. The property developer and contractor Arcona, which operates in Stockholm and Uppsala, Sweden, was acquired by the Veidekke group at year-end 2013. For information, please contact: Mats Nyström, CEO Veidekke Sweden, ph. +46 705 37 12 60Mikael Freudmann, Scius Partners, mikael.freudmann@scius.se, ph. +46 709 89 49 11 Veidekke press photos  

SaltX Technology Holding AB (publ) Interim report 2 2020

Interim report 2 2020Financial events  Second quarter  - Net sales amounted to MSEK 0.0 (0.9)- Operating profit/loss (EBIT) totaled MSEK -8.2 (-45.8)- Cash flow from operating activities amounted to MSEK -10.2 (-11.1) - Earnings per share before and after dilution amounted to SEK -0.09 (-0.66)  Year to date January - June - Net sales amounted to MSEK 0.1 (-0.8)- Operating profit/loss (EBIT) totaled MSEK -17.3 (-65.9)- Cash flow from operating activities amounted to MSEK -19.2 (-36.2) - Earnings per share before and after dilution amounted to SEK -0.21 (-0.96)

Vicore Pharma restarts mechanistic study with VP01 in systemic sclerosis

Gothenburg, August 25, 2020 – Vicore Pharma Holding (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces that patients are again being enrolled in the systemic sclerosis study after the pause due to the Covid-19 pandemic.After a five months pause due to the Covid-19 pandemic, Vicore Pharma has resumed enrolling patients in the mechanistic study with VP01 (C21) in patients with systemic sclerosis (SSc) and who also suffer from Raynaud’s phenomena (RP). ”We are very excited that the study has started again and if the Covid-19

Herantis Pharma Plc announces half year financial report January 1 – June 30, 2020 (unaudited)

Herantis Pharma Plc Company release August 25, 2020 at 9:00 AM Eastern European Summer TimeHerantis Pharma Plc announces half year financial report January 1 - June 30, 2020 (unaudited) · Clinical studies continue as planned despite Covid-19 pandemic · New CEO appointed in preparation for the next stage of company development Highlights in January-June 2020: · On Feb 25[th], Herantis Pharma Plc (“Herantis” or “Company”) announced topline results of its Phase I/II clinical trial with CDNF in Parkinson’s disease (PD). · On Apr 8[th], the Company’s Annual General Meeting

Swedbank Economic Outlook: The economic recovery remains fragile

The economic outlook has improved over the summer. Economic recovery is on firmer ground, but still needs support from fiscal policy. Sweden has increased its public debt during the covid-19 pandemic, but the costs for crisis support will be lower than earlier expected and there is still fiscal space, according to the Swedbank Economic Outlook report.The covid-19 pandemic continues to affect our everyday lives and the economy. The dramatic downturn in the world economy during the second quarter led global GDP to shrink by three percent this year. However, now there are some signs of

CONTINUED NEGATIVE IMPACT OF COVID-19

MAY 2020–JULY 2020 · Revenue: MSEK 2,507 (13,401) · Income before tax (EBT): MSEK -2,071 (1,490) · Income before tax and items affecting comparability: MSEK -784 (1,495) · Net income for the period: MSEK -2,365 (1,162) · Earnings per common share: SEK -6.18 (3.04) SIGNIFICANT EVENTS DURING THE QUARTER · SAS signs a SEK 3.3bn revolving credit facility agreement · SAS presents a revised business plan including measures to tackle the effects of the COVID-19 pandemic and revised sustainability goals · SAS presents a recapitalization plan to remedy the liquidity

THE POST COVID-19 SURGICAL BACKLOG: NOW IS THE TIME TO IMPLEMENT ERAS®

Applying ERAS® to reduce the Post Covid-19 Surgical backlog while at the same time “massively improve patient safety and outcomes” as well as “increasing capacity and driving down cost of care”. Members of the ERAS[®] Society Executive Committee; Prof Olle Ljungqvist, Prof Gregg Nelson, and Prof Nicolas Demartines have just published an editorial in the World Journal of Surgery describing the post COVID-19 surgical backlog and the role ERAS[®] can play in helping to deal with it. Read more  Encare offers the ERAS[®]

PRH has deregistered companies that have not filed their financial statements for registration

The Finnish Patent and Registration Office (PRH) has removed from the Finnish Trade Register ca. 3,500 limited liability companies and co-operatives that have not filed their financial statements for registration.The deregistered companies had not filed their financial statements despite reminder letters. The PRH had also informed the companies of the procedure using a number of communication channels. The deregistered companies are listed on the PRH website. · Read more about companies deregistered on 24 August 2020 in Finnish at prh.fi.  

OXE Marine AB (publ) Interim report 1 April to 30 June 2020

OXE Marine AB (publ) INTERIM REPORT 1 april - 30  juni 2020Second quarter (April - June 2020) ·Net turnover of SEK 21.8m (SEK 24.2m) ·Gross Profit of SEK 1.7m (SEK 0.3m) or gross margin of 8% (1%) ·Operating Loss/EBIT of SEK -12.2m (SEK -19.4m) ·Result for the period of SEK -14.3m (SEK -22.5m) ·Order book grew by 6% organically to EUR 5.4 m or SEK 57 m (EUR 5.1 m or SEK 56 m as at end of Q1 2020) First half of 2020 (January - June 2020) ·Year to date net turnover of SEK 32.1m (SEK 27.7m) ·Gross Profit of SEK 4.1m (SEK -10.4m) or gross

There are no items matching the current filter
There are no more items matching the current filter
Back to top